Asian Market Stocks That May Be Trading Below Estimated Value

Simply Wall St

As the Asian markets navigate a period of cautious optimism, recent developments in U.S.-China trade relations have spurred a positive sentiment, with key indices like China's CSI 300 reaching significant highs. In this environment, identifying stocks that may be trading below their estimated value can be particularly rewarding for investors seeking opportunities amidst shifting economic conditions.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

NameCurrent PriceFair Value (Est)Discount (Est)
Wanguo Gold Group (SEHK:3939)HK$29.50HK$58.6649.7%
Sunjin Beauty ScienceLtd (KOSDAQ:A086710)₩10670.00₩20978.2049.1%
SRE Holdings (TSE:2980)¥3070.00¥5980.2948.7%
Kolmar Korea (KOSE:A161890)₩79100.00₩155721.9949.2%
KeePer Technical Laboratory (TSE:6036)¥3445.00¥6838.9349.6%
Jiangxi Rimag Group (SEHK:2522)HK$19.11HK$37.6549.2%
Faraday Technology (TWSE:3035)NT$149.00NT$293.7349.3%
EROAD (NZSE:ERD)NZ$2.32NZ$4.6149.7%
Cosmax (KOSE:A192820)₩213000.00₩422219.9449.6%
Bloomberry Resorts (PSE:BLOOM)₱3.57₱7.1049.7%

Click here to see the full list of 271 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

Tsinghua Tongfang (SHSE:600100)

Overview: Tsinghua Tongfang Co., Ltd. operates in nuclear technology application, smart energy, and digital information sectors with a market cap of CN¥27.24 billion.

Operations: The company's revenue segments include nuclear technology application, smart energy, and digital information businesses.

Estimated Discount To Fair Value: 44.2%

Tsinghua Tongfang is trading at CN¥8.13, well below its estimated fair value of CN¥14.58, suggesting it may be undervalued based on cash flows. The company's earnings are forecast to grow significantly at 93.85% annually over the next three years, outpacing the broader Chinese market's growth rate of 24.9%. Although revenue growth is expected to be slower than 20% per year, it remains strong at 16.8%, surpassing market averages.

SHSE:600100 Discounted Cash Flow as at Aug 2025

Winning Health Technology Group (SZSE:300253)

Overview: Winning Health Technology Group Co., Ltd. offers digital health services to medical and health institutions in China, with a market cap of CN¥24.01 billion.

Operations: Winning Health Technology Group Co., Ltd. generates its revenue primarily through digital health services provided to medical and health institutions in China.

Estimated Discount To Fair Value: 47.1%

Winning Health Technology Group is trading at CN¥10.92, significantly below its estimated fair value of CN¥20.65, highlighting potential undervaluation based on cash flows. Despite a recent net loss of CN¥117.97 million for the first half of 2025, revenue growth is projected to outpace the Chinese market at 18.7% annually over three years. Earnings are expected to grow robustly by 63.42% per year, with profitability anticipated within this timeframe despite current challenges.

SZSE:300253 Discounted Cash Flow as at Aug 2025

Evergreen Aviation Technologies (TWSE:2645)

Overview: Evergreen Aviation Technologies Corporation offers aircraft maintenance services to airline partners both in Taiwan and internationally, with a market cap of NT$68.55 billion.

Operations: The company generates revenue primarily from providing aircraft maintenance services to airline partners in Taiwan and internationally.

Estimated Discount To Fair Value: 11%

Evergreen Aviation Technologies is trading at NT$183, below its estimated fair value of NT$205.51, suggesting undervaluation based on cash flows. Despite recent earnings declines, with a second-quarter net income drop to TWD 268.8 million from TWD 503.06 million year-on-year, future earnings are forecasted to grow significantly at 43.36% annually over the next three years, outpacing the Taiwan market's growth rate of 15.9%. However, dividend sustainability remains questionable due to insufficient coverage by earnings or free cash flows.

TWSE:2645 Discounted Cash Flow as at Aug 2025

Key Takeaways

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Tsinghua Tongfang might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com